EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 120.52

Change

-0.36 (-0.30)%

Market Cap

USD 0.70B

Volume

4.35K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.43 (+0.84%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.15 (+0.88%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.20 (+0.71%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.23 (+0.94%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.56 (+0.39%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

+0.23 (+0.49%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.45 (+0.88%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.72 (+0.69%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.18 (+0.79%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.15% 75% C 74% C
Dividend Return 1.17% 40% F 26% F
Total Return 15.32% 79% B- 76% C+
Trailing 12 Months  
Capital Gain 13.33% 50% F 54% F
Dividend Return 1.40% 37% F 25% F
Total Return 14.73% 54% F 56% F
Trailing 5 Years  
Capital Gain 43.54% 64% D 66% D+
Dividend Return 5.54% 62% D 33% F
Total Return 49.09% 68% D+ 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.39% 56% F 56% F
Dividend Return 7.32% 60% D- 57% F
Total Return 0.93% 63% D 43% F
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 65% D 72% C
Risk Adjusted Return 87.01% 89% A- 90% A-
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike